06. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in oestrogen receptor positive breast cancer patients

Boland, Michael R.; Gilroy, Darina; Nugent, Timothy; Kennedy, J. S.; Alazawi, Dhaffir; Boyle, Terence J.; Connolly, Elizabeth

doi:10.1016/j.ejso.2019.01.192

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results challenge conventional thought around chemosensitivity in breast cancer. Specifically, to our knowledge, this study is 1 of only 2 studies 25 to show a high rate of axillary pCR in patients with ER-positive, PR-negative, HER2-negative disease. In our study, 13 (43%) of 30 patients in this subgroup achieved an axillary pCR, which compares favourably with the response seen in patients with TNBC, a group that is preferentially offered neoadjuvant chemotherapy given the high chance of exceptional response.…”

Section: Discussionmentioning

confidence: 86%

“…In our study, 13 (43%) of 30 patients in this subgroup achieved an axillary pCR, which compares favourably with the response seen in patients with TNBC, a group that is preferentially offered neoadjuvant chemotherapy given the high chance of exceptional response. 15,18 Boland and colleagues 25 showed that a negative progesterone receptor status has a strong influence on rates of both breast and axillary response to neoadjuvant treatment. This may have farreaching consequences for ER-positive/PR-negative patients, who may not otherwise be considered for neoadjuvant systemic treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer

Ladak

Chua

Lesniak

et al. 2022

cjs

View full text Add to dashboard Cite

Background:The ability to accurately predict which patients will achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy could help identify those who could safely be spared the potential morbidity of axillary lymph node dissection. We performed a retrospective analysis of a cohort of clinically node-positive patients managed with neoadjuvant chemotherapy with the goal of identifying predictors of axillary pCR.Methods: Eligible patients were aged 18 years or older, had clinical T1-T4, N1-N3, M0 breast cancer and received neoadjuvant chemotherapy followed by surgical axillary lymph node staging between 2001 and 2017 at Misericordia Hospital, Edmonton, Alberta. Patient data, including tumour characteristics, details of neoadjuvant chemotherapy, imaging results before and after neoadjuvant chemotherapy, and final pathologic analysis, were collected from the appropriate provincial electronic data repositories. We summarized the data using descriptive statistics. We characterized associations between clinical/tumour characteristics and pCR using univariate and multivariate regression analysis.Results: Of the 323 patients included in the study, 130 (40.2%) achieved axillary pCR. Absence of residual disease in the breast was associated with axillary pCR (odds ratio 6.74, 95% confidence interval 2.89-15.67). HER2-positive, triple-negative and ER-positive/PR-negative/HER2-negative tumours were significantly associated with a pCR on univariate analysis; the association trended toward significance on multivari ate analysis.

show abstract

Section: Discussionmentioning

confidence: 86%